TrialClinical cancer research : an official journal of the American Association for Cancer Research2022

FDA Approval Summary: Ivosidenib for the Treatment of Patients with Advanced Unresectable or Metastatic, Chemotherapy Refractory Cholangiocarcinoma with an IDH1 Mutation.

Sandra J Casak et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.